Summaries

Non-traditional antibiotics: A pipeline review and an analysis of key development challenges

Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress in a meaningful way (go here for Pew’s recent survey of the development landscape). Providing insights into the challenges of this area, two valuable and complementary articles on non-traditional antibiotics have recently

Read More »

Lancet: 10-20-30 targets to address AMR by 2030

Dear All (wonkish alert … but definitely worth the effort! Refill your coffee!),Ramanan Laxminarayan and about 40 colleagues from around the world have just published in the Lancet a GLORIOUS collection of papers on the theme of “Sustainable Access to Effective Antibiotics.”There are six papers in total for you to digest: An Executive Summary, four papers with

Read More »

Developing antibiotics for children: There are no easy answers

Aside: If you’ve enjoyed the prior discussions of movies to inspire antibiotic R&D and very apropos given the theme of today’s newsletter, please check out the newly released 4-minute YouTube discussion of a scene from Master and Commander in which antibiotics could have saved a young man’s arm! Dear All (Wonkish alert! There’s a lot of

Read More »

Vaccines to turn back the tide of antimicrobial resistance

Dear All, See also this related newsletter: 14 Jul 2022, entitled “WHO Vaccine Pipeline Review; CDC On Impact Of COVID On AMR.” As part of their Immunization Agenda 2030: A Global Strategy to Leave No One Behind, WHO have now published an AMR-focused action framework that summarizes ways we should seek to use vaccines both

Read More »

New antibiotics are not being registered or sold in Europe in a timely manner

Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored AMR Conference (really a wonderful conference, thank you Team BEAM, go here to listen to the sessions), we tumbled onto a really, really disturbing trend: New antibiotics are not being registered or sold in Europe in

Read More »

All-in cost of a new antibiotic from discovery to 10 years on market

Dear All (and with thanks to Kevin Krause for co-authoring this newsletter), The elements that contribute to the all-in cost of an antibiotic have been reviewed in two prior newsletters: 6 Mar 2020 (focused on cost of R&D to approval): What does an antibiotic cost to develop? What is it worth? How to afford it? 7 Jan

Read More »

Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin

This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part 3, Part 4, and Part 5. Also relevant is the 5 April 2024 newsletter entitled “48,015 → 0: Antibacterial Discovery Is Hard. Really, Really Hard.“ Dear All (wonkish note alert!), The recent newsletter on chemicals, drugs, and halicin (link, see

Read More »

Chemicals vs. drugs (Part 3): XKCD has the final word

This newsletter is part of a series — here are the links to Part 1, Part 2, (this one is Part 3), Part 4, and Part 5.  Dear All, As a coda to the two newsletters on Chemicals, Drugs, and Halicin (link and link), XKCD gets the final word: Image reproduced with permission from https://xkcd.com/1217/. And, you might

Read More »
Scroll to Top